245 results on '"Fenaux, P."'
Search Results
2. EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
3. Caractérisation immunologique (cytokinique et cellulaire) des manifestations auto-immunes et inflammatoires associées aux syndromes myélodysplasiques
4. Identification des mutations somatiques et analyse des mécanismes immunologiques au cours des manifestations auto-immunes et/ou inflammatoires associées à la leucémie myélomonocytaire chronique
5. Efficacité et tolérance de l’azacitidine au cours du syndrome VEXAS avec et sans syndrome myélodysplasique : données du registre français
6. CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial
7. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?
8. Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION
9. Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION
10. GERMLINE CHEK2 MUTATED MDS PATIENTS
11. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: CXCL8 SECRETED BY IMMATURE GRANULOCYTES INHIBITS WILD-TYPE STEM AND PROGENITOR CELL EXPANSION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
12. Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES THROUGH IGFBP2
13. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
14. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
15. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS
16. Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases
17. Efficacité et tolérance de azacitidine dans les manifestations dysimmunes associées aux SMD/LMMC : essai prospectif de phase II
18. Dermatose par infiltrat à cellules dendritiques plasmacytoïdes ou indéterminées matures chez des patients atteints d’hémopathie myéloïde, une étude de 14 cas
19. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
20. Utilisation de l’azacitidine dans le VEXAS chez des patients porteurs d’un syndrome myélodysplasique : données du registre Français VEXAS
21. Observatoire français de 116 patients avec un syndrome VEXAS : corrélation phénotype–génotype et prise en charge
22. Caractéristiques phénotypiques et mutationnelles des maladies auto-immunes et inflammatoires (MAI) associées aux néoplasies myéloprolifératives (NMP)
23. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III
24. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III
25. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III
26. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
27. Infiltrat myéloïde clonal identifié par next generation sequencing dans les lésions cutanées associées aux syndromes myélodysplasiques et leucémies myélomonocytaires chroniques
28. Maladie de Still et PseudoStill associés aux SMD et LMMC : Étude nationale Française
29. PCN3 Changes in Transfusion Burden (TB), Hemoglobin (Hb), Serum Ferritin (SF), and Iron Chelation Therapy (ICT) Use in Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts Treated With Luspatercept From the MEDALIST Study
30. Syndrome de pseudo-Behçet et autres manifestations dysimmunitaires associées aux syndromes myélodysplasiques avec trisomie 8
31. Myelodysplasia cutis
32. Prévalence et pronostic des manifestations thrombotiques dans les maladies inflammatoires et auto-immunes associées aux syndromes myélodysplasiques : étude cas-témoins rétrospective multicentrique française
33. 1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres
34. Caractéristiques cliniques, évolution et prise en charge des thrombopénies immunologiques associées aux syndromes myélodysplasiques et leucémies myélomonocytaires chroniques : une étude multicentrique rétrospective comparative
35. Identification de mutations clonales identiques dans les xanthélasma palpébraux de maladie d’Erdheim-Chester associés à des leucémies myélomonocytaires chroniques: à propos de 3 cas
36. Prise en charge des syndromes myélodysplasiques en 2019 : mise au point
37. Manifestations auto-immunes et inflammatoires associées aux syndromes myélodysplasiques : effet de l’azacitidine sur les différentes populations immunitaires
38. The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
39. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A
40. Manifestations auto-immunes et inflammatoires associées aux syndromes myélodysplasiques avec trisomie 8 : étude cas-contrôles française rétrospective
41. MDS with Isolated Trisomy 8: A type of MDS Frequently Associated with Myeloproliferative Features? A Report by the GFM
42. Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). A Report of 9 Cases
43. Impact of Red Blood Cell Transfusions on Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS (EUMDS) Registry
44. Prognostic Value of Early Drop in Platelets in Lower-Risk MDS. A Sub-Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry
45. Impact of Gene Mutations on Response to Lenalidomide and OS in Lower-Risk Non-Del(5Q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAS)
46. Azacitidine Improves Outcome in High Risk MDS Patients with Chromosome 7 Abnormalities: Retrospective Comparison of GESMD and GFM Registries
47. Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
48. Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment
49. Health-Related Quality of Life is Substantially Impaired in Lower-Risk MDS when Compared with Reference Populations and Significantly Affects Overall Survival
50. Challenging IWG2006 Response Criteria: Results of a Randomized Study of Epoetin Alfaversus Placebo in Anemic Lower Risk MDS Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.